Related Experiment Video
Updated: Nov 10, 2025
Generation of Organ-conditioned Media and Applications for Studying Organ-specific Influences on Breast Cancer Metastatic Behavior
Published on: June 13, 2016
Inhibition of the Growth of Breast Cancer-Associated Brain Tumors by the Osteocyte-Derived Conditioned Medium
Tomohiko Sano1,2, Xun Sun1,3, Yan Feng1,3
1Department of Biomedical Engineering, Indiana University Purdue University Indianapolis, Indianapolis, IN 46202, USA.
Abstract:
The brain is a common site of metastasis from advanced breast cancer but few effective treatments are available. We examined a therapeutic option with a conditioned medium (CM), focusing on the role of Lrp5 and β-catenin in Wnt signaling, and IL1ra in osteocytes. Osteocytes presented the innate anti-tumor effect and the overexpression of the above genes strengthened their action. In a mouse model, the injection of their CM inhibited mammary tumors and tumor-driven osteolysis. Importantly, Lrp5- and/or IL1ra-overexpressing osteocytes or the local administration of β-catenin-overexpressing CM markedly inhibited brain tumors. In the transport analysis, tumor-suppressing factors in CM were shown to diffuse through the skull. Mechanistically, the CM with overexpression of the above genes downregulated oncogenic genes such as MMP9, Runx2, TGFβ, and Snail in breast cancer cells. Also, the CM with β-catenin overexpression downregulated CXCL1 and CXCL5 and upregulated tumor suppressors such as LIMA1, DSP, p53, and TRAIL in breast cancer cells. Notably, whole-genome proteomics revealed that histone H4 was enriched in CM and acted as an atypical tumor suppressor. Lrp5-overexpressing MSCs were also shown to act as anti-tumor agents. Collectively, this study demonstrated the therapeutic role of engineered CM in brain tumors and the tumor-suppressing action of extracellular histone H4. The result sheds light on the potential CM-based therapy for breast cancer-associated brain metastases in a minimally invasive manner.
Insights
Engineered conditioned medium (CM) shows therapeutic potential against breast cancer brain metastases. Overexpressing specific genes in osteocytes and CM enhances anti-tumor effects, inhibiting tumor growth and osteolysis via novel mechanisms.
Area of Science:
- Oncology
- Molecular Biology
- Biomedical Engineering
Background:
- Brain metastasis from advanced breast cancer is a significant clinical challenge with limited effective treatments.
- Osteocytes possess innate anti-tumor properties that can be potentially enhanced for therapeutic applications.
- Wnt signaling pathway components, including Lrp5 and β-catenin, play crucial roles in cellular processes relevant to cancer.
Purpose of the Study:
- To investigate the therapeutic efficacy of engineered conditioned medium (CM) derived from osteocytes against breast cancer brain metastases.
- To elucidate the roles of Lrp5, β-catenin in Wnt signaling, and IL1ra in osteocyte-mediated anti-tumor activity.
- To explore the potential of extracellular histone H4 as a novel anti-tumor agent.
Main Methods:
- Generation and characterization of conditioned medium (CM) from osteocytes with genetic modifications (overexpression of Lrp5, β-catenin, IL1ra).
- In vivo studies using a mouse model to assess the efficacy of CM in inhibiting mammary tumors, osteolysis, and brain metastases.
- Analysis of CM's molecular mechanisms, including gene expression profiling in cancer cells and whole-genome proteomics.
Main Results:
- CM from engineered osteocytes significantly inhibited mammary tumors and tumor-driven osteolysis in a mouse model.
- Local administration of CM, particularly with β-catenin overexpression, markedly inhibited brain tumors.
- Tumor-suppressing factors in CM were found to penetrate the skull, and CM downregulated oncogenic genes while upregulating tumor suppressors in cancer cells. Extracellular histone H4 was identified as a key tumor suppressor in CM.
Conclusions:
- Engineered conditioned medium represents a promising therapeutic strategy for managing breast cancer brain metastases.
- Overexpression of Lrp5, β-catenin, and IL1ra in osteocytes enhances their anti-tumor capabilities, transferable via CM.
- Extracellular histone H4 contributes to the anti-tumor effects of CM, offering a novel therapeutic target for minimally invasive treatment.
